Report of Foreign Issuer (6-k)
April 18 2016 - 9:52AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
April 18, 2016
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo
Nordisk A/S – Reduction of the share capital
Bagsværd, Denmark, 18 April 2016
– At Novo Nordisk’s
Annual General Meeting on 18 March 2016, it was dec ided to reduc e the company’s B share capital from DKK 412,512,800 to
DKK 402,512,800 by cancellation of part of the company’s portfolio of own B shares at a nominal value of DKK 10,000,000 divided
into 50,000,000 B shares of DKK 0.20 each.
Today, Novo Nordisk
has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled
nominally DKK 10,000,000 B shares. After the reduction of the share capital, the company’s share capital is nominally
DKK 510,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK
402,512,800.
The reduction in the share capital will not affect Novo Nordisk’s
share repurchase programme which will continue as previously announced.
Novo Nordisk is
a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us
experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders
and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,000 people in 75 countries and markets its products
in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube
Further information
Media:
|
Anne Margrethe
Hauge
|
+45 3079 3450
|
amhg@novonordisk.com
|
|
|
|
Investors:
|
Peter Hugreffe Ankersen
|
+45 3075 9085
|
phak@novonordisk.com
|
Daniel Bohsen
|
+45 3079 6376
|
dabo@novonordisk.com
|
Melanie Raouzeos
|
+45 3075 3479
|
mrz@novonordisk.com
|
Kasper Veje
|
+45 3079 8519
|
kpvj@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
|
CVR no:
24 25 67 90
|
|
|
Company announcement No 29 / 2016
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: April 18, 2016
|
NOVO NORDISK A/S
Lars Rebien Sørensen,
Chief Executive Officer
|
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novo Nordisk (NYSE:NVO)
Historical Stock Chart
From Apr 2023 to Apr 2024